Leukemia Research
Volume 34, Issue 2 , Pages 173-176 , February 2010

Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemia

  • Jean-Marie Bruey

      Affiliations

    • Hematology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, United States
    • Corresponding Author InformationCorresponding author at: Quest Diagnostics Nichols Institute, Building A, Hematopathology/Oncology R&D, 33608 Ortega Highway, San Juan Capistrano, CA 92675, United States. Tel.: +1 949 728 4622; fax: +1 949 728 7781.
    • ,
  • Hagop Kantarjian

      Affiliations

    • Leukemia Department, MD Anderson Cancer Center, University of Texas, Houston, TX, United States
    • ,
  • Zeev Estrov

      Affiliations

    • Leukemia Department, MD Anderson Cancer Center, University of Texas, Houston, TX, United States
    • ,
  • Zhong Zhang

      Affiliations

    • Hematology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, United States
    • ,
  • Wanlong Ma

      Affiliations

    • Hematology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, United States
    • ,
  • Ferras Albitar

      Affiliations

    • Hematology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, United States
    • ,
  • Adam Abdool

      Affiliations

    • Hematology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, United States
    • ,
  • Deborah Thomas

      Affiliations

    • Leukemia Department, MD Anderson Cancer Center, University of Texas, Houston, TX, United States
    • ,
  • Chenhsiung Yeh

      Affiliations

    • Hematology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, United States
    • ,
  • Susan O’Brien

      Affiliations

    • Leukemia Department, MD Anderson Cancer Center, University of Texas, Houston, TX, United States
    • ,
  • Maher Albitar

      Affiliations

    • Hematology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, United States

Received 19 March 2009 ,Revised 25 June 2009 ,Accepted 18 July 2009.

References 

  1. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710–1715
  2. Brown DC, Gatter KC. Ki67 protein: the immaculate deception?. Histopathology. 2002;40:2–11
  3. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–322
  4. Endl E, Gerdes J. The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res. 2000;257:231–237
  5. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005;23:7212–7220
  6. Khatami A, Hugosson J, Wang W, Damber JE. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy. Scand J Urol Nephrol. 2009;43:12–18
  7. Oshima CT, Iriya K, Forones NM. Ki-67 as a prognostic marker in colorectal cancer but not in gastric cancer. Neoplasma. 2005;52:420–424
  8. Ferrara C, Tessari G, Poletti A, et al. Ki-67 and c-jun expression in pancreatic cancer: a prognostic marker?. Oncol Rep. 1999;6:1117–1122
  9. Sulik M, Guzinska-Ustymowicz K. Expression of Ki-67 and PCNA as proliferating markers in prostate cancer. Rocz Akad Med Bialymst. 2002;47:262–269
  10. Uzoaru I, Rubenstein M, Mirochnik Y, Slobodskoy L, Shaw M, Guinan P. An evaluation of the markers p53 and Ki-67 for their predictive value in prostate cancer. J Surg Oncol. 1998;67:33–37
  11. Bassan R, Gatta G, Tondini C, Willemze R. Adult acute lymphoblastic leukaemia. Crit Rev Oncol Hematol. 2004;50:223–261
  12. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350:1535–1548
  13. Cooper S. Reappraisal of serum starvation, the restriction point, G0, and G1 phase arrest points. FASEB J. 2003;17:333–340
  14. Celis JE, Celis A. Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: subdivision of S phase. Proc Natl Acad Sci U S A. 1985;82:3262–3266
  15. Gallee MP, van Steenbrugge GJ, ten Kate FJ, Schroeder FH, van der Kwast TH. Determination of the proliferative fraction of a transplantable, hormone-dependent, human prostatic carcinoma (PC-82) by monoclonal antibody Ki-67: potential application for hormone therapy monitoring. J Natl Cancer Inst. 1987;79:1333–1340
  16. Lee J, Im YH, Lee SH, et al. Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer. Cancer Chemother Pharmacol. 2008;61:569–577
  17. Jones RL, Salter J, A’hern R, et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2008;
  18. Ahlin C, Aaltonen K, Amini RM, Nevanlinna H, Fjallskog ML, Blomqvist C. Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values?. Histopathology. 2007;51:491–498
  19. Hrushesky WJ, Retsky M, Baum M, Demicheli R. Re: Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007;99:1053–1054
  20. Nomura Y, Yoshida S, Karube K, et al. Estimation of the relationship between caspase-3 expression and clinical outcome of Burkitt's and Burkitt-like lymphoma. Cancer Sci. 2008;99:1564–1569
  21. Rogers A, Joe Y, Manshouri T, et al. Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia. Blood. 2004;103:2799–2801
  22. Manshouri T, Do KA, Wang X, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood. 2003;101:2507–2513
  23. Giles FJ, Vose JM, Do KA, et al. Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease. Br J Haematol. 2003;123:850–857
  24. Albitar M, Do KA, Johnson MM, et al. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer. 2004;101:999–1008
  25. Giles FJ, Albitar M. Plasma-based testing as a new paradigm for clinical testing in hematologic diseases. Expert Rev Mol Diagn. 2007;7:615–623
  26. Oh EJ, Kahng J, Kim Y, et al. Expression of functional markers in acute lymphoblastic leukemia. Leuk Res. 2003;27:903–908
  27. Qiao L, Shiff SJ, Rigas B. Sulindac sulfide inhibits the proliferation of colon cancer cells: diminished expression of the proliferation markers PCNA and Ki-67. Cancer Lett. 1997;115:229–234
  28. Zheng JN, Pei DS, Mao LJ, et al. Inhibition of renal cancer cell growth in vitro and in vivo with oncolytic adenovirus armed short hairpin RNA targeting Ki-67 encoding mRNA. Cancer Gene Ther. 2009;16:20–32

PII: S0145-2126(09)00377-4

doi: 10.1016/j.leukres.2009.07.030

Leukemia Research
Volume 34, Issue 2 , Pages 173-176 , February 2010

Article Tools

* Image Usage & Resolution